{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T18:40:09Z","timestamp":1791830409039,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T00:00:00Z","timestamp":1713830400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020154","name":"Protagonist Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.clml.2024.04.003","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T13:14:18Z","timestamp":1713273258000},"page":"512-522","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9040-7415","authenticated-orcid":false,"given":"Andrew T.","family":"Kuykendall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer T.","family":"Fine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Kremyanskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2024.04.003_bib0001","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.clml.2024.04.003_bib0002","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0003","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.04.003_bib0004","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1007\/s00432-015-1983-5","article-title":"Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011","volume":"141","author":"Deadmond","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"10.1016\/j.clml.2024.04.003_bib0005","doi-asserted-by":"crossref","first-page":"656","DOI":"10.7326\/0003-4819-123-9-199511010-00003","article-title":"Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia","volume":"123","year":"1995","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.clml.2024.04.003_bib0006","first-page":"1197","article-title":"A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database","volume":"57","author":"Brunner","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.clml.2024.04.003_bib0007","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","article-title":"Myeloproliferative neoplasms and thrombosis","volume":"122","author":"Barbui","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.04.003_bib0008","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1200\/JCO.2005.07.062","article-title":"Vascular and neoplastic risk in a large cohort of patients with polycythemia vera","volume":"23","author":"Marchioli","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0009","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41375-021-01447-3","article-title":"Normal life expectancy for polycythemia vera (PV) patients is possible","volume":"36","author":"Abu-Zeinah","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0010","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/bjh.15648","article-title":"A guideline for the diagnosis and management of polycythaemia vera","volume":"184","author":"McMullin","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.04.003_bib0011","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms V.1.2024. \u00a9 National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed May 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0012","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/S2352-3026(22)00046-1","article-title":"Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations","volume":"9","author":"Marchetti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0013","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood.2018834044","article-title":"How I treat polycythemia vera","volume":"134","author":"Spivak","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.04.003_bib0014","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.leukres.2018.06.001","article-title":"The real-world outcomes of treating polycythemia vera: Physician adherence to treatment guidelines","volume":"70","author":"Jackson Chornenki","year":"2018","journal-title":"Leuk Res"},{"issue":"20","key":"10.1016\/j.clml.2024.04.003_bib0015","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"issue":"33","key":"10.1016\/j.clml.2024.04.003_bib0016","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/JCO.2012.42.3863","article-title":"Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs","volume":"30","author":"Emanuel","year":"2012","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0017","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1200\/JCO.2015.62.9337","article-title":"Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease","volume":"34","author":"Geyer","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.04.003_bib0018","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1186\/s12885-016-2208-2","article-title":"Myeloproliferative neoplasms (MPNs) have a significant impact on patients' overall health and productivity: the MPN Landmark survey","volume":"16","author":"Mesa","year":"2016","journal-title":"BMC Cancer"},{"issue":"7 Suppl 3","key":"10.1016\/j.clml.2024.04.003_bib0019","first-page":"S36","article-title":"Diagnosis and management of polycythemia vera: Proceedings from a multidisciplinary roundtable","volume":"7","author":"Raedler","year":"2014","journal-title":"Am Health Drug Benefits"},{"issue":"9","key":"10.1016\/j.clml.2024.04.003_bib0020","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3109\/10428194.2012.759656","article-title":"Age-related differences in disease characteristics and clinical outcomes in polycythemia vera","volume":"54","author":"Stein","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"10.1016\/j.clml.2024.04.003_bib0021","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/leu.2013.163","article-title":"Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study","volume":"27","author":"Tefferi","year":"2013","journal-title":"Leukemia"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0022","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/blood-2022-157255","article-title":"Ropeginterferon alfa-2b versus standard therapy for low-risk patients with polycythemia vera. Final results of Low-PV randomized phase II trial","volume":"140","author":"Barbui","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.clml.2024.04.003_bib0023","doi-asserted-by":"crossref","first-page":"2533","DOI":"10.1007\/s00277-019-03793-w","article-title":"Hematocrit levels and thrombotic events in patients with polycythemia vera: an analysis of Veterans Health Administration data","volume":"98","author":"Parasuraman","year":"2019","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.003_bib0024","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa1208500","article-title":"Cardiovascular events and intensity of treatment in polycythemia vera","volume":"368","author":"Marchioli","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0025","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1365-2141.1995.tb08411.x","article-title":"Interpretation of measured red cell mass and plasma volume in adults: expert panel on radionuclides of the International Council for Standardization in Haematology","volume":"89","author":"Pearson","year":"1995","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0026","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2019.09.601","article-title":"Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: an analysis from the REVEAL study","volume":"20","author":"Grunwald","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.04.003_bib0027","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40164-016-0031-8","article-title":"Patterns of hydroxyurea use and clinical outcomes among patients with polycythemia vera in real-world clinical practice: a chart review","volume":"5","author":"Parasuraman","year":"2016","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.04.003_bib0028","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00277-023-05089-6","article-title":"Real-world treatments and thrombotic events in polycythemia vera patients in the USA","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.04.003_bib0029","doi-asserted-by":"crossref","first-page":"e915","DOI":"10.1016\/j.clml.2021.06.023","article-title":"Real-world dosing patterns of ruxolitinib in patients with polycythemia vera who are resistant to or intolerant of hydroxyurea","volume":"21","author":"Altomare","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2024.04.003_bib0030","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3324\/haematol.2016.152769","article-title":"Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea","volume":"102","author":"Alvarez-Larr\u00e1n","year":"2017","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.clml.2024.04.003_bib0031","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1002\/cncr.30325","article-title":"Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists\/oncologists in the United States: findings from the MPN Landmark survey","volume":"123","author":"Mesa","year":"2017","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0032","doi-asserted-by":"crossref","first-page":"607","DOI":"10.3324\/haematol.2017.180448","article-title":"Non-adherence to treatment with cytoreductive and\/or antithrombotic drugs is frequent and associated with an increased risk of complications in patients with polycythemia vera or essential thrombocythemia (OUEST study)","volume":"103","author":"Le Calloch","year":"2018","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.clml.2024.04.003_bib0033","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/cncr.22365","article-title":"The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients","volume":"109","author":"Mesa","year":"2007","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.clml.2024.04.003_bib0034","doi-asserted-by":"crossref","first-page":"193","DOI":"10.18773\/austprescr.2021.052","article-title":"Non-anaemic iron deficiency","volume":"44","author":"Balendran","year":"2021","journal-title":"Aust Prescr"},{"issue":"10","key":"10.1016\/j.clml.2024.04.003_bib0035","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-018-0207-9","article-title":"Dysregulated iron metabolism in polycythemia vera: etiology and consequences","volume":"32","author":"Ginzburg","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.04.003_bib0036","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.leukres.2017.01.032","article-title":"Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy","volume":"56","author":"Verstovsek","year":"2017","journal-title":"Leuk Res"},{"issue":"6","key":"10.1016\/j.clml.2024.04.003_bib0037","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1080\/10428194.2016.1246733","article-title":"The potential role of hematocrit control on symptom burden among polycythemia vera patients: insights from the CYTO-PV and MPN-SAF patient cohorts","volume":"58","author":"Scherber","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.clml.2024.04.003_bib0038","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.1182\/blood.V126.23.5187.5187","article-title":"Burden of phlebotomy in patients with polycythemia vera in the United States: baseline data from the REVEAL study","volume":"126","author":"Boccia","year":"2015","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2024.04.003_bib0039","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1007\/s00277-017-3082-y","article-title":"The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey","volume":"96","author":"Harrison","year":"2017","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0040","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1182\/blood-2022-156445","article-title":"Quality of life and symptom burden of patients with MPN during treatment with hydroxyurea or pegylated interferon-alpha2: results from a randomized controlled trial","volume":"140","author":"Knudsen","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0041","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1182\/blood-2022-162714","article-title":"Impact of chronic disease and its burden on aspects of quality of life in a unique sub-population of myeloproliferative neoplasm patients","volume":"140","author":"Loffelhardt","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0042","doi-asserted-by":"crossref","first-page":"5279","DOI":"10.1182\/blood-2022-156494","article-title":"Measuring the incidence of distress and supportive oncology utilization among patients with myeloproliferative neoplasms: a single center experience","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.04.003_bib0043","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.psym.2018.01.006","article-title":"Associations of physical and psychologic symptom burden in patients with Philadelphia chromosome-negative myeloproliferative neoplasms","volume":"59","author":"McFarland","year":"2018","journal-title":"Psychosomatics"},{"issue":"9","key":"10.1016\/j.clml.2024.04.003_bib0044","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.clml.2018.05.020","article-title":"Patient-reported outcomes data from REVEAL at the time of enrollment (baseline): a prospective observational study of patients with polycythemia vera in the United States","volume":"18","author":"Mesa","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"1","key":"10.1016\/j.clml.2024.04.003_bib0045","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s12885-018-4322-9","article-title":"Impact of myeloproliferative neoplasms on patients' employment status and work productivity in the United States: results from the living with MPNs survey","volume":"18","author":"Yu","year":"2018","journal-title":"BMC Cancer"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0046","doi-asserted-by":"crossref","first-page":"3974","DOI":"10.1182\/blood-2022-162657","article-title":"The burden of illness and the incremental burden of transfusion dependence in myelofibrosis in the United States","volume":"140","author":"Gerds","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.04.003_bib0047","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.leukres.2012.01.006","article-title":"The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes","volume":"36","author":"Platzbecker","year":"2012","journal-title":"Leuk Res"},{"issue":"7","key":"10.1016\/j.clml.2024.04.003_bib0048","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1185\/03007990802160834","article-title":"Costs, quality of life, treatment satisfaction and compliance in patients with beta-thalassemia major undergoing iron chelation therapy: the ITHACA study","volume":"24","author":"Scalone","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clml.2024.04.003_bib0049","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.ctrv.2018.07.005","article-title":"Systematic reviews of economic burden and health-related quality of life in patients with acute myeloid leukemia","volume":"69","author":"Bosshard","year":"2018","journal-title":"Cancer Treat Rev"},{"issue":"12","key":"10.1016\/j.clml.2024.04.003_bib0050","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.clml.2018.08.009","article-title":"Clinical and disease characteristics from REVEAL at time of enrollment (baseline): prospective observational study of patients with polycythemia vera in the United States","volume":"18","author":"Grunwald","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0051","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13280","article-title":"Therapeutic phlebotomy is safe in children with sickle cell anaemia and can be effective treatment for transfusional iron overload","volume":"169","author":"Aygun","year":"2015","journal-title":"Br J Haematol"},{"issue":"19","key":"10.1016\/j.clml.2024.04.003_bib0052","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1182\/blood.2021012743","article-title":"A randomized phase 3 trial of interferon-\u03b1 vs hydroxyurea in polycythemia vera and essential thrombocythemia","volume":"139","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0053","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/s41375-020-0945-3","article-title":"Significant association of cutaneous adverse events with hydroxyurea: results from a prospective non-interventional study in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - On behalf of the German Study Group-MPN","volume":"35","author":"Stegelmann","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.04.003_bib0054","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.04.003_bib0055","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200335","article-title":"Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera","volume":"2","author":"Barbui","year":"2023","journal-title":"NEJM Evidence"},{"issue":"3","key":"10.1016\/j.clml.2024.04.003_bib0056","doi-asserted-by":"crossref","first-page":"e226","DOI":"10.1016\/S2352-3026(19)30207-8","article-title":"Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study","volume":"7","author":"Kiladjian","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.clml.2024.04.003_bib0057","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(22)00102-8","article-title":"Ruxolitinib versus best available therapy in inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): 5-year follow up of a randomised, phase 3b study","volume":"9","author":"Passamonti","year":"2022","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.clml.2024.04.003_bib0058","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1038\/s41375-019-0487-8","article-title":"Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study","volume":"33","author":"Barbui","year":"2019","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0059","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.17192","article-title":"Second primary malignancy in myelofibrosis patients treated with ruxolitinib","volume":"193","author":"Polverelli","year":"2021","journal-title":"Br J Haematol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0060","first-page":"2910","article-title":"Incidence of infections and second cancers in philadelphia chromosome-negative patients with myeloproliferative neoplasms treated with ruxolitinib","volume":"130","author":"Ritchie","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.clml.2024.04.003_bib0061","doi-asserted-by":"crossref","first-page":"4089","DOI":"10.1002\/cam4.2107","article-title":"Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 2233 patients","volume":"8","author":"Mora","year":"2019","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.clml.2024.04.003_bib0062","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1182\/bloodadvances.2019000646","article-title":"Second primary malignancies in ruxolitinib-treated myelofibrosis: real-world evidence from 219 consecutive patients","volume":"3","author":"Maffioli","year":"2019","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2024.04.003_bib0063","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2019.1688323","article-title":"Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis","volume":"61","author":"Tremblay","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0064","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jaad.2021.10.004","article-title":"A 10-year retrospective cohort study of ruxolitinib and association with nonmelanoma skin cancer in patients with polycythemia vera and myelofibrosis","volume":"86","author":"Lin","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.003_bib0065","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/ejh.12787","article-title":"Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms","volume":"98","author":"Hansen","year":"2017","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.04.003_bib0066","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/s13023-022-02343-4","article-title":"Healthcare access, satisfaction, and health-related quality of life among children and adults with rare diseases","volume":"17","author":"Bogart","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.clml.2024.04.003_bib0067","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1002\/mgg3.315","article-title":"Living with a rare disorder: a systematic review of the qualitative literature","volume":"5","author":"von der Lippe","year":"2017","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.clml.2024.04.003_bib0068","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.freeradbiomed.2018.07.003","article-title":"Erythropoietic regulators of iron metabolism","volume":"133","author":"Ganz","year":"2019","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"10.1016\/j.clml.2024.04.003_bib0069","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1007\/s12325-022-02421-w","article-title":"TMPRSS6 as a therapeutic target for disorders of erythropoiesis and iron homeostasis","volume":"40","author":"Ganz","year":"2023","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.clml.2024.04.003_bib0070","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/MOH.0000000000000747","article-title":"Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis","volume":"30","author":"Handa","year":"2023","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.clml.2024.04.003_bib0071","unstructured":"Clinicaltrials.gov. A phase 3 study of rusfertide in patients with polycythemia vera (VERIFY). 2023. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05210790. Accessed July 5, 2023."},{"key":"10.1016\/j.clml.2024.04.003_bib0072","series-title":"Presented at: European Hematology Association 2023 Congress","article-title":"Targeted therapy of uncontrolled erythrocytosis in polycythemia vera with the hepcidin mimetic, rusfertide: blinded randomized withdrawal results of the REVIVE study","author":"Kremyanskaya","year":"2023"},{"issue":"S3","key":"10.1016\/j.clml.2024.04.003_bib0073","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000970968.04468.60","article-title":"Rusfertide (PTG-300) improves polycythemia vera (PV) related symptoms in PV patients","volume":"7","author":"Kuykendall","year":"2023","journal-title":"HemaSphere"},{"issue":"Suppl 2","key":"10.1016\/j.clml.2024.04.003_bib0074","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/S2152-2650(22)01462-8","article-title":"MPN-469 Rusfertide (PTG-300) treatment interruption reverses hematological gains and upon reinitiation, restoration of clinical benefit observed in patients with polycythemia vera","volume":"22","author":"Pemmaraju","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2024.04.003_bib0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa2308809","article-title":"Rusfertide, a hepcidin mimetic, for control of erythrocytosis in polycythemia vera","volume":"390","author":"Kremyanskaya","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.04.003_bib0076","unstructured":"Clinicaltrials.gov. A study to evaluate sapablursen (formerly ISIS 702843, IONIS-TMPRSS6-LRx) in patients with polycythemia vera. 2023. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05143957. Accessed July 5, 2023."},{"key":"10.1016\/j.clml.2024.04.003_bib0077","unstructured":"Clinicaltrials.gov. Study to assess SLN124 in patients with polycythemia vera (SLN). 2023. Available at: https:\/\/clinicaltrials.gov\/study\/NCT05499013. Accessed August 29, 2023."},{"key":"10.1016\/j.clml.2024.04.003_bib0078","unstructured":"Clinicaltrials.gov. Bomedemstat in patients with polycythemia vera. 2023. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT05558696. Accessed July 5, 2023."},{"key":"10.1016\/j.clml.2024.04.003_bib0079","unstructured":"Clinicaltrials.gov. IMG-7289 in patients with essential thrombocythemia (ET) or polycythemia vera (PV). 2023. Available at: https:\/\/www.clinicaltrials.gov\/study\/NCT04262141. Accessed July 5, 2023."},{"key":"10.1016\/j.clml.2024.04.003_bib0080","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1120911","article-title":"LSD1 inhibitors for cancer treatment: focus on multi-target agents and compounds in clinical trials","volume":"14","author":"Noce","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clml.2024.04.003_bib0081","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.HS9.0000847000.38667.91","article-title":"P1033: A phase 2 study of the LSD1 inhibitor IMG-7289 (bomedemstat) for the treatment of essential thrombocythemia (ET)","volume":"6","author":"Palandri","year":"2022","journal-title":"Hemasphere"},{"issue":"suppl 1","key":"10.1016\/j.clml.2024.04.003_bib0082","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2021-148682","article-title":"A phase 2 study of the LSD1 inhibitor IMG-7289 (bomedemstat) for the treatment of advanced myelofibrosis","volume":"138","author":"Gill","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.04.003_bib0083","unstructured":"Clinicaltrials.gov. Study on efficacy and safety of givinostat versus hydroxyurea in patients with polycythemia vera (GIV-IN PV). 2024. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06093672. Accessed April 2, 2024."},{"issue":"3","key":"10.1016\/j.clml.2024.04.003_bib0084","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-021-00445-z","article-title":"Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1\/2 studies and a compassionate use program","volume":"11","author":"Rambaldi","year":"2021","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2024.04.003_bib0085","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1080\/13543784.2020.1761323","article-title":"Givinostat: an emerging treatment for polycythemia vera","volume":"29","author":"Chifotides","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"issue":"7","key":"10.1016\/j.clml.2024.04.003_bib0086","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2024.04.003_bib0087","unstructured":"Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) for Myeloproliferative Neoplasms V.3.2022. \u00a9 National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed August 29, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001514?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001514?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T07:47:49Z","timestamp":1729842469000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001514"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2152265024001514"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.04.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}